December 2025
1. SAMARASEKERA U
   Deniz Gokengin-responding to HIV/AIDS in Turkiye.
   Lancet Infect Dis. 2025;25:1278.
   

   >> Share

   
   
2. KIRBY T
   Seema Sahay-linking behavioural science and HIV research.
   Lancet Infect Dis. 2025;25:1277.
   

   >> Share

   
   October 2025
3. SUNG J, Nantale M, Nalutaaya A, Biche P, et al
   Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study.
   Lancet Infect Dis. 2025 Oct 7:S1473-3099(25)00536.
   

   >> Share

   
   September 2025
4. HOFFMANN DAHL E, Jiba DF, Casas EC, Jonckheere S, et al
   Monkeypox virus-HIV co-infections in Sierra Leone.
   Lancet Infect Dis. 2025 Sep 12:S1473-3099(25)00542.
   

   >> Share

   
   
5. METCALFE JZ, Weir IR, Scarsi KK, Mendoza-Ticona A, et al
   A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial.
   Lancet Infect Dis. 2025 Sep 4:S1473-3099(25)00436.
   

   >> Share

   
   
6. TIRLANGI PK, Khan AR, Soneja M, Gupta N, et al
   Preventing vertical HIV transmission in India: the final push.
   Lancet Infect Dis. 2025 Sep 2:S1473-3099(25)00535.
   

   >> Share

   
   August 2025
7. 
   Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
   Lancet Infect Dis. 2025 Aug 28:S1473-3099(25)00361.
   

   >> Share

   
   
8. LADHANI SN, Ramsay ME, Fifer H
   What can be learnt from the world's first national vaccination programme against gonorrhoea.
   Lancet Infect Dis. 2025 Aug 20:S1473-3099(25)00468.
   

   >> Share

   
   July 2025
9. ANSARI R
   Memory as resistance: HIV/AIDS, care, and collective futures.
   Lancet Infect Dis. 2025 Jul 24:S1473-3099(25)00471.
   

   >> Share

   
   
10. VAN EIJK AM, Stepniewska K, Khairallah C, Rodriguez E, et al
    The impact of sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive treatment for the prevention of malaria in pregnancy in Africa: an updated systematic review and meta-analysis.
    Lancet Infect Dis. 2025 Jul 14:S1473-3099(25)00219.
    

    >> Share

    
    
11. MINJA LT, van der Feltz I, Manyama C, Mpagama S, et al
    Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial.
    Lancet Infect Dis. 2025 Jul 8:S1473-3099(25)00289.
    

    >> Share

    
    
12. PERUMAL R, Naidoo K
    The patient pursuit of safe treatment options for tuberculosis.
    Lancet Infect Dis. 2025 Jul 8:S1473-3099(25)00362.
    

    >> Share

    
    
13. HEINRICH N, Manyama C, Koele SE, Mpagama S, et al
    Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial.
    Lancet Infect Dis. 2025 Jul 8:S1473-3099(25)00213.
    

    >> Share

    
    
14. CHALKIAS S, Dennis P, Petersen D, Radhakrishnan K, et al
    Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial.
    Lancet Infect Dis. 2025 Jul 7:S1473-3099(25)00236.
    

    >> Share

    
    June 2025
15. MDLENYANI L, Mohamed Z, Stadler JAM, Mtwa N, et al
    Treatment outcomes of bedaquiline-resistant tuberculosis: a retrospective and matched cohort study.
    Lancet Infect Dis. 2025 Jun 18:S1473-3099(25)00218.
    

    >> Share

    
    
16. MAERTENS JA, Thompson GR 3rd, Spec A, Donovan FM, et al
    Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.
    Lancet Infect Dis. 2025 Jun 17:S1473-3099(25)00224.
    

    >> Share

    
    
17. SEDDON JA, Achar J, Malik AA, Hughes J, et al
    Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosis.
    Lancet Infect Dis. 2025 Jun 5:S1473-3099(25)00157.
    

    >> Share

    
    
18. GATTI FD, Nodari JZ, Sousa TJ, Mendonca GC, et al
    Neuroinvasive Oropouche virus in a patient with HIV from extra-Amazonian Brazil.
    Lancet Infect Dis. 2025 Jun 3:S1473-3099(25)00352.
    

    >> Share

    
    May 2025
19. PATERSON A, Mughogho KK, Cheyne A, Kabajaasi O, et al
    The (Re)-emerging And ePidemic Infectious Diseases (RAPID) Stigma Scales: a cross-outbreak scale development and pyschometric validation study.
    Lancet Infect Dis. 2025 May 30:S1473-3099(25)00161.
    

    >> Share

    
    
20. PATON NI, Cousins C, Sari IP, Burhan E, et al
    Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial.
    Lancet Infect Dis. 2025 May 22:S1473-3099(25)00151.
    

    >> Share

    
    
21. GRANSKOG L, Saadeh K, Lorenz K, Quint J, et al
    Effect of JYNNEOS vaccination on mpox clinical progression: a case-control study.
    Lancet Infect Dis. 2025 May 21:S1473-3099(25)00180.
    

    >> Share

    
    April 2025
22. VANBAELEN T, Manoharan-Basil SS, Kenyon C
    Doxy-PEP could select for ceftriaxone resistance in Neisseria gonorrhoeae.
    Lancet Infect Dis. 2025 Apr 22:S1473-3099(25)00234.
    

    >> Share

    
    
23. LAYTON GR, Veater JB, Thombre R, Afshar B, et al
    Disseminated Mycoplasma pneumoniae infection presenting with polyarthritis and endocarditis.
    Lancet Infect Dis. 2025;25:e253-e254.
    

    >> Share

    
    March 2025
24. SASO A, Kanteh E, Jeffries D, Okoye M, et al
    The effect of pertussis vaccination in pregnancy on the immunogenicity of acellular or whole-cell pertussis vaccination in Gambian infants (GaPS): a single-centre, randomised, controlled, double-blind, phase 4 trial.
    Lancet Infect Dis. 2025 Mar 25:S1473-3099(25)00072.
    

    >> Share

    
    
25. MCCLURE M, Gandhi M
    Threat of HIV and tuberculosis drug resistance after US funding cuts.
    Lancet Infect Dis. 2025 Mar 20:S1473-3099(25)00209.
    

    >> Share

    
    
26. HILLUS D, Le NH, Tober-Lau P, Fietz AK, et al
    Safety and effectiveness of MVA-BN vaccination against mpox in at-risk individuals in Germany (SEMVAc and TEMVAc): a combined prospective and retrospective cohort study.
    Lancet Infect Dis. 2025 Mar 18:S1473-3099(25)00018.
    

    >> Share

    
    
27. BORGES AH, Russell M, Tait D, Scriba TJ, et al
    Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlle
    Lancet Infect Dis. 2025 Mar 5:S1473-3099(24)00814.
    

    >> Share

    
    February 2025
28. PROAL AD, Aleman S, Bomsel M, Brodin P, et al
    Targeting the SARS-CoV-2 reservoir in long COVID.
    Lancet Infect Dis. 2025 Feb 10:S1473-3099(24)00769.
    

    >> Share

    
    January 2025
29. DUNSMUIR H
    HIV and rights for queer communities in Ghana.
    Lancet Infect Dis. 2025 Jan 27:S1473-3099(25)00066.
    

    >> Share

    
    December 2024
30. PAINTER C, Limmathurotsakul D, Roberts T, van Doorn HR, et al
    Sustainable antimicrobial resistance surveillance: time for a global funding mechanism.
    Lancet Infect Dis. 2024 Dec 17:S1473-3099(24)00649.
    

    >> Share

    
    
31. KIRBY T
    Justyna Kowalska-reaching underserved people with HIV.
    Lancet Infect Dis. 2024;24:1303.
    

    >> Share

    
    November 2024
32. BAGCCHI S
    Spreading awareness about HIV transmission.
    Lancet Infect Dis. 2024 Nov 28:S1473-3099(24)00803.
    

    >> Share

    
    
33. NAIDOO K, Perumal R
    First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis.
    Lancet Infect Dis. 2024 Nov 26:S1473-3099(24)00653.
    

    >> Share

    
    
34. HOLT E
    Gilead under fire over HIV drug licensing.
    Lancet Infect Dis. 2024 Nov 8:S1473-3099(24)00747.
    

    >> Share

    
    October 2024
35. DAS NEVES MARTINS FE, Chiang JO, Nunes BTD, Ribeiro BFR, et al
    Newborns with microcephaly in Brazil and potential vertical transmission of Oropouche virus: a case series.
    Lancet Infect Dis. 2024 Oct 15:S1473-3099(24)00617.
    

    >> Share

    
    
36. BAGCCHI S
    HIV stigma in health-care settings in Europe and central Asia.
    Lancet Infect Dis. 2024;24:e622.
    

    >> Share

    
    
37. ORKIN C, Ring K
    Implementing long-acting injectable cabotegravir and rilpivirine in Africa.
    Lancet Infect Dis. 2024;24:1060-1061.
    

    >> Share

    
    September 2024
38. WASSERMAN S, Donovan J, Kestelyn E, Watson JA, et al
    Advancing the chemotherapy of tuberculous meningitis: a consensus view.
    Lancet Infect Dis. 2024 Sep 26:S1473-3099(24)00512.
    

    >> Share

    
    
39. OLBRICH L, Franckling-Smith Z, Larsson L, Sabi I, et al
    Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: a secondary analysis of the RaPaed-TB study.
    Lancet Infect Dis. 2024 Sep 20:S1473-3099(24)00494.
    

    >> Share

    
    
40. PROCHAZKA M, Vinti P, Hoxha A, Seale A, et al
    Temporary adaptations to sexual behaviour during the mpox outbreak in 23 countries in Europe and the Americas: findings from a retrospective cross-sectional online survey.
    Lancet Infect Dis. 2024 Sep 18:S1473-3099(24)00531.
    

    >> Share

    
    
41. BAPOLISI WA, Krasemann S, Wayengera M, Kirenga B, et al
    Mpox outbreak-tecovirimat resistance, management approaches, and challenges in HIV-endemic regions.
    Lancet Infect Dis. 2024 Sep 10:S1473-3099(24)00591.
    

    >> Share

    
    
42. HOLT E
    Setbacks and advances in the global HIV response.
    Lancet Infect Dis. 2024;24:e554.
    

    >> Share

    
    
43. PANNIKOTTU J, Reuter A, Pietersen E, Makhanda G, et al
    Waiting is no longer an option for household contacts of people with drug-resistant tuberculosis.
    Lancet Infect Dis. 2024;24:947-949.
    

    >> Share

    
    August 2024
44. STARBUCK E
    Biopolitical precarity for women with HIV in South Africa.
    Lancet Infect Dis. 2024 Aug 26:S1473-3099(24)00572.
    

    >> Share

    
    
45. VANBAELEN T, Manoharan-Basil SS, Kenyon C
    Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance.
    Lancet Infect Dis. 2024 Aug 21:S1473-3099(24)00502.
    

    >> Share

    
    
46. RACCAGNI AR, Castagna A, Nozza S
    Gonorrhoea and chlamydia screening for asymptomatic people with HIV and HIV PrEP users: open issues.
    Lancet Infect Dis. 2024 Aug 13:S1473-3099(24)00528.
    

    >> Share

    
    July 2024
47. GRAY GE, Mngadi K, Lavreys L, Nijs S, et al
    Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial.
    Lancet Infect Dis. 2024 Jul 19:S1473-3099(24)00358.
    

    >> Share

    
    
48. LEHMANN C, Schommers P
    The need for novel approaches to HIV-1 vaccine development.
    Lancet Infect Dis. 2024 Jul 19:S1473-3099(24)00398.
    

    >> Share

    
    June 2024
49. DECROO T, Mesic A, Decuyper I
    Longevity of modified standard short treatment regimens for rifampicin-resistant tuberculosis.
    Lancet Infect Dis. 2024 Jun 13:S1473-3099(24)00294.
    

    >> Share

    
    
50. KOROTYCH O, Achar J, Gurbanova E, Hovhannesyan A, et al
    Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
    Lancet Infect Dis. 2024 Jun 13:S1473-3099(24)00228.
    

    >> Share

    
    
51. JOSEPH DAVEY D, de Voux A, Hlatshwayo L, Nelson A, et al
    Prevention of congenital syphilis within antenatal PrEP services in South Africa: missed opportunities.
    Lancet Infect Dis. 2024;24:571-572.
    

    >> Share

    
    May 2024
52. KITYO C, Mambule IK, Musaazi J, Sokhela S, et al
    Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
    Lancet Infect Dis. 2024 May 28:S1473-3099(24)00289.
    

    >> Share

    
    
53. MOLINA JM, Bercot B, Assoumou L, Rubenstein E, et al
    Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 x 2 factorial design.
    Lancet Infect Dis. 2024 May 23:S1473-3099(24)00236.
    

    >> Share

    
    
54. CEVIK M, Thompson LC, Upton C, Rolla VC, et al
    Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
    Lancet Infect Dis. 2024 May 17:S1473-3099(24)00223.
    

    >> Share

    
    April 2024
55. JIN SL, Kolis J, Parker J, Proctor DA, et al
    Social histories of public health misinformation and infodemics: case studies of four pandemics.
    Lancet Infect Dis. 2024 Apr 19:S1473-3099(24)00105.
    

    >> Share

    
    
56. 
    Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet Infect Dis. 2024 Apr 16:S1473-3099(24)00158.
    

    >> Share

    
    
57. PELUSO MJ, Swank ZN, Goldberg SA, Lu S, et al
    Plasma-based antigen persistence in the post-acute phase of COVID-19.
    Lancet Infect Dis. 2024 Apr 8:S1473-3099(24)00211.
    

    >> Share

    
    March 2024
58. CHAKAYA J, Fatma R, Cader M, Harries AD, et al
    Post-tuberculosis lung disease: is there a light at the end of tunnel?
    Lancet Infect Dis. 2024 Mar 22:S1473-3099(24)00136.
    

    >> Share

    
    
59. NAIDOO K, Perumal R, Cox H, Mathema B, et al
    The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis-lessons from the South African experience.
    Lancet Infect Dis. 2024 Mar 22:S1473-3099(24)00144.
    

    >> Share

    
    
60. LADHANI SN, White PJ, Campbell H, Mandal S, et al
    Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK.
    Lancet Infect Dis. 2024 Mar 20:S1473-3099(24)00031.
    

    >> Share

    
    
61. 
    Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00007.
    

    >> Share

    
    
62. STUCK L, Klinkenberg E, Abdelgadir Ali N, Basheir Abukaraig EA, et al
    Prevalence of subclinical pulmonary tuberculosis in adults in community settings: an individual participant data meta-analysis.
    Lancet Infect Dis. 2024 Mar 12:S1473-3099(24)00011.
    

    >> Share

    
    
63. COHN J, Mendelson M, Kanj SS, Shafiq N, et al
    Accelerating antibiotic access and stewardship: a new model to safeguard public health.
    Lancet Infect Dis. 2024 Mar 11:S1473-3099(24)00070.
    

    >> Share

    
    
64. DAS M
    UNICEF report reveals gender gaps persist in HIV.
    Lancet Infect Dis. 2024;24:e159.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share